Luoyi Bio-Pharmaceutical

Luoyi Biopharmaceutical is a biotechnology company headquartered in Suzhou, China, dedicated to the development of innovative therapies using circular RNA (circRNA) technology. The company's proprietary platform focuses on enhancing the stability and translation efficiency of RNA, addressing the inherent limitations of traditional linear mRNA. Luoyi Bio is advancing a diverse pipeline that includes vaccines for infectious diseases, such as COVID-19, and therapeutic candidates for oncology and rare diseases. Supported by prominent investors like GL Ventures and Qiming Venture Partners, the company integrates advanced LNP delivery systems with its RNA engineering expertise. Luoyi Bio aims to establish itself as a leader in the next generation of RNA-based medicine.